

# Ruth Dannenfelser

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6590580/ruth-dannenfelser-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9  
papers

319  
citations

7  
h-index

10  
g-index

10  
ext. papers

478  
ext. citations

15.3  
avg, IF

2.79  
L-index

#	Paper	IF	Citations
9	An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes.. <i>Cancer Cell</i> , <b>2022</b> , 40, 524-544.e5	24.3	2
8	SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	61
7	Selective Neuronal Vulnerability in Alzheimer's Disease: A Network-Based Analysis. <i>Neuron</i> , <b>2020</b> , 107, 821-835.e12	13.9	35
6	Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies. <i>Cell Systems</i> , <b>2020</b> , 11, 215-228.e5	10.6	26
5	Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab. <i>Onc Immunology</i> , <b>2018</b> , 7, e1457598	7.2	13
4	IFN-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment. <i>Cell</i> , <b>2017</b> , 170, 127-141.e15	56.2	104
3	Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 4716-4725	3.3	6
2	Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity. <i>Oncotarget</i> , <b>2017</b> , 8, 57121-57133	3.3	24
1	Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. <i>Molecular Cancer Research</i> , <b>2015</b> , 13, 493-501	6.6	48